Stock Code: 600380 Stock Short Name: 健康元
JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO., LTD.
2022 Annual Report
Important Notice
I. The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisors
and senior management of the Company hereby warrant the truthfulness, accuracy and
completeness of the contents of this annual report (the “Report”), and that there are no false
representations, misleading statements or material omissions contained in the Report, and
severally and jointly accept legal responsibility.
II.All directors of the Company attended the Board meeting.
III. GrantThornton (Special General Partnership) issued a standard unqualified audit report
for the Company.
IV. Mr. Zhu Baoguo (朱保国), the person-in-charge of the Company, and Mr. Qiu Qingfeng
(邱庆丰), the person-in-charge of accountingworkandthe person-in-charge of theaccounting
department (the head of the accounting department) declare that they hereby warrant the
truthfulness, accuracy and completeness of the financial statements contained in the Report.
V. Profit distribution plan or plan for conversion of capital reserve to share capital approved
by the Board resolution during the Reporting Period
Based on the audit conducted by Grant Thornton (Special General Partnership), in 2022, the Parent
Company generated net profit of RMB849,731,957.95, 10% of which was contributed to the
statutory surplus reserve, namely RMB84,973,195.80, the remainder of which, together with
undistributed profits for the last year of RMB1,400,174,178.18 and gain on disposal of other equity
investments of RMB80,749,859.60, subtracting cash dividends for the last year of
RMB277,557,631.65, is the profits available for distribution to shareholders for the year of
RMB1,968,125,168.28. The Company plans to distribute cash dividends for the fiscal year 2022,
based on the total number of shares for dividend distribution, which is defined by the total shares of
Company, minus the shares in the Share Repurchase Account, on the equity registration date
designated by the annual profit distribution plan. The Company plans to distribute cash dividend of
RMB1.80 (tax inclusive) for every 10 shares of to all shareholders of the Company, and the
remaining undistributed profits will be carried forward to the following year.
VI. Risk declaration for the forward-looking statements
√Applicable □N/A
The Report contains forward-looking statements which involve the future plans, development
strategies, etc. of the Company, yet do not constitute substantive undertakings of the Company to
investors. Investors should exercise caution prior to making investment decisions.
VII. Whether there is non-operating use of funds by the controlling shareholder and their
related parties
No
VIII. Whether there is a violation of the prescribed decision-making procedures to provide
external guarantees
No
IX. Whether more than half of directors cannot warrant the truthfulness, accuracy and
completeness of the Report disclosed by the Company
No
X. Significant risk warnings
There is no exceptionally significant risk that will have a material impact on the production and
operation of the Company during the Reporting Period. In this Report, the Company has elaborated
on the risks and countermeasures that the Company may face in the course of production and
operation, including industry policy risk, market risk, risk of safety and environmental protection,
risk in price and supply of raw materials and R&D risk. For more information, please refer to
“Potential risks” part in Chapter 3 Management Discussion and Analysis.
XI. Others
□Applicable √N/A
Table of Contents
Important Notice ...... 2
Chairman's Statement...... 5
Financial Highlights...... 10
Chapter 1 Definitions ...... 12
Chapter 2 Company Profile and Major Financial Indicators ...... 14
Chapter 3 Management Discussion and Analysis...... 19
Chapter 4 Corporate Governance...... 78
Chapter 5 Environmental and Social Responsibility...... 99
Chapter 6 Major Events...... 123
Chapter 7 Changes in Equity and Shareholders...... 141
Chapter 8 Information on Preferred Shares...... 148
Chapter 9 Information on Bonds...... 149
Chapter 10 Financial Statements...... 150
The Financial Statements signed and sealed by the person-in-charge of
the Company, the person-in-charge of the Company's accounting work
and the person-in-charge of the accounting department (the head of the
accounting department)
List of documents The original document of the auditors’ report sealed by the accounting
available for inspection firm and signed and sealed by the certified public accountants
The original copies of all documents and announcements of the
Company which have been disclosed to the public on th
查看PDF原文
